Rapt Therapeutics, Inc. - RAPT STOCK NEWS

RAPT Therapeutics, Inc. (Nasdaq: RAPT) announced the presentation of clinical efficacy data from its Phase 1b trial of RPT193, an oral CCR4 inhibitor for moderate-to-severe atopic dermatitis. The presentation will occur at the 4th Inflammatory Skin Disease Summit in New York, from November 3-6, 2021. The trial is designed to demonstrate the efficacy of RPT193 compared to a placebo. This is part of RAPT's commitment to developing therapies for significant unmet needs in oncology and inflammatory diseases.

RAPT Therapeutics announced positive topline results from its Phase 1b clinical trial of RPT193 for moderate-to-severe atopic dermatitis, presented at the EADV Congress. The trial demonstrated significant efficacy across key exploratory endpoints including EASI and vIGA, with benefits observed persisting two weeks post-treatment. RPT193 was well tolerated, showing a clean safety profile with no serious adverse events. The company plans to advance RPT193 to a Phase 2b trial in atopic dermatitis and a Phase 2a trial in asthma, highlighting its potential in treating inflammatory diseases.

RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Brian Wong will present at the 2021 Cantor Virtual Healthcare Conference on September 27, 2021, at 2:00 p.m. EST. The company focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases, with two drug candidates, FLX475 and RPT193, targeting CCR4 receptors. For access to the live webcast and archived recordings, visit the RAPT Therapeutics website.

RAPT Therapeutics announced it will present clinical safety and efficacy data for RPT193, an oral CCR4 inhibitor, from its Phase 1b trial targeting moderate-to-severe atopic dermatitis at the upcoming 30th European Academy of Dermatology and Venereology Congress on September 30, 2021. The presentation highlights a significant step in RAPT's ongoing commitment to develop novel therapies for unmet needs in oncology and inflammatory diseases.

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2021 – RAPT Therapeutics (Nasdaq: RAPT) announced that Brian Wong, M.D., Ph.D., President and CEO, will present at key investor conferences in September. Notably, he will speak at the Wells Fargo 2021 Virtual Healthcare Conference on September 9 at 8:00 a.m. EST and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 a.m. EST. For live webcasts and archived recordings, visit RAPT's official website. RAPT focuses on oral therapies for oncology and inflammatory diseases, advancing drug candidates targeting CCR4.

RAPT Therapeutics reported Q2 2021 financial results, highlighting a net loss of $16.1 million, up from $12.4 million year-over-year. R&D expenses rose to $13.2 million, driven by clinical trial costs for FLX475. The company successfully completed a public offering, generating $134.6 million, enhancing its cash position to $223.3 million. Notable achievements include positive topline results from the Phase 1b trial of RPT193 for atopic dermatitis. RAPT remains optimistic about advancing its drug development initiatives in oncology and inflammatory diseases.

RAPT Therapeutics has successfully closed its underwritten public offering of 4,356,060 shares of common stock at $33.00 per share, raising approximately $143.7 million before expenses. This includes 568,181 shares sold due to underwriters' full exercise of their option. The offering was made under an effective shelf registration statement filed with the SEC. J.P. Morgan, SVB Leerink, and Piper Sandler acted as joint lead book-running managers for this offering.

RAPT Therapeutics, a clinical-stage biopharmaceutical company, has announced a public offering of 3,787,879 shares at $33.00 each, aiming for approximately $125 million in gross proceeds. The offering, set to close on June 18, 2021, is managed by J.P. Morgan, SVB Leerink, and Piper Sandler. A 30-day option for underwriters to purchase an additional 568,181 shares is also available. This offering follows a shelf registration with the SEC that was effective on November 16, 2020.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) has announced a public offering of $125 million in common stock, with an option for underwriters to purchase an additional $18.75 million. The offering is contingent on market conditions and is governed by a previously filed shelf registration statement with the SEC. J.P. Morgan, SVB Leerink, and Piper Sandler are the lead managers for the offering. This fundraising aims to support RAPT's development of oral therapies targeting significant unmet needs in oncology and inflammatory diseases.